Gadolinium-based contrast agents (GBCAs) used in MRI and angiography contain a chelated form of the toxic heavy metal that was assumed to clear the body shortly after intravenous administration. [1] ...

Add Yahoo as a preferred source to see more of our stories on Google. A magnetic resonance imaging (MRI) scan is an important tool to help doctors see what’s happening inside your body. But new, ...

Mangaciclanol’s Phase I trial showed it was well tolerated, with no serious adverse events or clinically significant findings.

MRI scans are powerful diagnostic tools. In the 1990s they became commonly used, and contrast agents that contain the rare earth metal gadolinium were created to enhance the sharpness of the images.

Approval marks a major milestone in reducing gadolinium exposure while maintaining diagnostic performance, aligning with clinical guidance to use the lowest effective dose MONTREAL, April 17, 2026 ...

Please provide your email address to receive an email when new articles are posted on . The risk of developing nephrogenic systemic fibrosis was low with the use of gadolinium-based contrast agents ...

GE HealthCare Technologies Inc. GEHC recently announced that the first patient has been dosed in its Phase 2/3 LUMINA ...

BERLIN--(BUSINESS WIRE)--Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an ...

Simulations reveal details about the magnetic interactions between gadolinium contrast agents used in MRI scans and their environment. You can keep your best guesses. Engineers at Rice University's ...

GE HealthCare Technologies (NasdaqGS:GEHC) has dosed the first patient in its global LUMINA Phase 2/3 trial of mangaciclanol, ...

GE HealthCare announces first patient dosed in Phase 2/3 LUMINA trial for manganese-based MRI contrast agent under FDA Fast Track designation ...